688639 华恒生物
2026/09 - 九个月
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额173,360104,547199,795301,417357,425
投资活动产生之现金流量净额(314,010)(643,456)(930,095)(1,127,050)(342,005)
筹资活动产生之现金流量净额445,216409,219780,7501,024,6126,460
汇率变动对现金及现金等价物的影响(13,724)(1,147)12,0166,5415,246
现金及现金等价物净增加/(减少)290,842(130,837)62,465205,52027,126
期初现金及现金等价物余额284,122414,959352,494146,974119,847
期末现金及现金等价物余额574,964284,122414,959352,494146,974